Group 1 - The controlling shareholder's actual controller, Ma Li, plans to reduce holdings from October 21, 2025, to January 20, 2026, by no more than 9.6333 million shares, accounting for 2% of the company's total share capital [1] - As of January 20, 2026, Ma Li has reduced holdings by 6.41 million shares, which is 1.33% of the total shares, through centralized bidding and block trading [1] - The reduction included selling 4.81 million shares at 12.07 yuan per share from November 18, 2025, to January 14, 2026, and 1.6 million shares at 10.36 yuan per share from January 13 to January 19, 2026 [1] Group 2 - Liu Shuqin has not reduced any holdings, and the reduction plan period has expired [1]

Group 1 - The company, Sai Sheng Pharmaceutical, announced that its subsidiary, Beijing Sai Er Biological Pharmaceutical Co., Ltd., has recently received the high-tech enterprise certificate from the Beijing Science and Technology Commission, Beijing Finance Bureau, and the State Taxation Administration of Beijing [2] - This certificate is a re-certification following the expiration of the previous one, allowing the company to pay corporate income tax at a rate of 15% for the fiscal years 2025 to 2027 [2]

北京赛升药业股份有限公司（以下简称"公司"）于 2025 年 9 月 19 日在巨 潮资讯网披露了《关于公司控股股东、实际控制人的一致行动人减持股份的预披 露公告》（公告编号：2025-036）。马丽女士和刘淑芹女士因自身资金需求拟通 过集中竞价交易方式、大宗交易方式等深圳证券交易所认可的合法方式减持股份 数量合计不超过 9,633,328 股，即不超过公司目前总股本的 2%。减持期间为自 本公告披露之日起 15 个交易日后的三个月内（即 2025 年 10 月 21 日至 2026 年 1 月 20 日）。 证券代码：300485 证券简称：赛升药业 公告编号：2026-004 北京赛升药业股份有限公司 关于公司控股股东、实际控制人的一致行动人 减持计划期限届满暨减持股份实施情况的公告 公司控股股东、实际控制人的一致行动人马丽女士保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、本次减持计划的实施符合《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》《上市公司股东、董监 ...

Core Viewpoint - Sai Sheng Pharmaceutical (300485.SZ) has received the "High-tech Enterprise Certificate" from the Beijing Municipal Science and Technology Commission, which allows its subsidiary, Beijing Sai Er Biological Pharmaceutical Co., Ltd., to benefit from tax incentives for high-tech enterprises for three years [1] Group 1 - The certificate number is GR202511004935, issued on December 2, 2025, and is valid for three years [1] - The recognition as a high-tech enterprise is a re-certification following the expiration of the previous certificate [1] - From the year of recognition, Sai Er Biological will enjoy a corporate income tax rate of 15% for the years 2025, 2026, and 2027, in accordance with national tax incentive policies for high-tech enterprises [1]

Core Viewpoint - Sai Sheng Pharmaceutical (300485.SZ) has received the "High-tech Enterprise Certificate" from the Beijing Municipal Science and Technology Commission, which allows its subsidiary, Beijing Sai Er Biological Pharmaceutical Co., Ltd., to benefit from tax incentives for high-tech enterprises [1] Group 1 - The certificate number is GR202511004935, issued on December 2, 2025, and is valid for three years [1] - This recognition is a re-certification following the expiration of the previous certificate [1] - The company will enjoy a corporate income tax rate of 15% for the years 2025, 2026, and 2027 under the national tax incentive policy for high-tech enterprises [1]

证券代码：300485 证券简称：赛升药业 公告编号：2026-003 北京赛升药业股份有限公司 关于审计机构变更项目合伙人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京赛升药业股份有限公司（以下简称"公司"）于2025年3月27日、2025 年4月21日召开第五届董事会第六次会议、2024年年度股东大会，审议通过了《关 于续聘致同会计师事务所（特殊普通合伙）为公司2025年度审计机构的议案》， 同意续聘致同会计师事务所（特殊普通合伙）（以下简称"致同所"）为公司2025 年度审计机构，具体内容详见公司于2025年3月29日在巨潮资讯网披露的《关于 续聘公司2025年度财务及内部控制审计机构的公告》（公告编号：2025-011）。 近日，公司收到致同所出具的《关于拟变更项目合伙人的沟通函》，现将有 关情况公告如下： 一、本次变更项目合伙人的基本情况 致同所作为公司 2025 年度财务报表及内部控制审计机构，原指派的项目合 伙人为刘均山。鉴于致同所内部工作调整，拟将项目合伙人由刘均山变更为闫磊。 二、本次变更的项目合伙人信息 1、基本信息 闫磊，2 ...

北京赛升药业股份有限公司 关于子公司通过高新技术企业认定的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京赛升药业股份有限公司（以下简称"公司"）子公司北京赛而生物药业 有限公司（以下简称"赛而生物"）于近日收到北京市科学技术委员会、北京市 财政局、国家税务总局北京市税务局联合颁发的《高新技术企业证书》，证书编 号为GR202511004935，发证时间为2025年12月2日，有效期为三年。 证券代码：300485 证券简称：赛升药业 公告编号：2026-002 本次高新技术企业的认定系原证书有效期满后的重新认定，根据国家对高新 技术企业税收优惠政策的相关规定，赛而生物自本次通过高新技术企业认定当年 起三年内（即 2025 年度、2026 年度、2027 年度）可享受国家关于高新技术企业 所得税优惠政策，即按 15%的税率缴纳企业所得税。本次通过高新技术企业认定 事项不会对公司当期经营业绩产生重大影响。 特此公告。 北京赛升药业股份有限公司 董 事 会 2026年1月20日 ...

Core Viewpoint - The company is focusing on increasing revenue, reducing costs, and improving efficiency to enhance capital utilization and profitability while strategically planning for future project investments [1] Group 1: Strategic Development - The company has established a group development layout based on five strategic platforms: R&D innovation platform, pharmaceutical industry chain innovation platform (including high-end formulations and oral formulations production bases, active pharmaceutical ingredient production base, and modern Chinese medicine production base), collaborative technology innovation platform, capital industry platform, and seed industry innovation platform [1]

Group 1 - The core point of the article is that Sai Sheng Pharmaceutical (300485) reported a total of 34,157 shareholders as of January 10, 2026 [1]

Group 1 - The core point of the article is that Sai Sheng Pharmaceutical (300485.SZ) experienced a significant drop in its stock price, with a decline of 4.11% to 11.66 yuan [2] - The company announced that shareholder Ms. Ma Li will reduce her stake by selling a total of 3.3282 million shares, which represents 0.69% of the company's total share capital [2]